SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
